A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Recruiting now

Conditions studied: Tetanus

In brief

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Key facts

Study ID

NCT07107932

Run by

Zhuhai Trinomab Pharmaceutical Co., Ltd.

People needed

10000

Starts

2025-07-31

Expected to finish

2029-03-30

Last updated by the study team

2026-01-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;
• 2. Provided signed informed consent by themselves or their legal representatives.

You may not qualify if…

• None

Where it is running

• Shaoxing Central Hospital — Shaoxing, Zhejiang, China (enrolling)
• The Second Affiliated Hospital of Shantou University — Shantou, Guangdong, China
• Xiangyun County People's Hospital — Xiangyun, Yunnan, China
• Zhoushan Putuo District People's Hospital — Zhoushan, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.